Navigation Links
New class of drug targets skin cancer
Date:5/7/2013

7 May, 2013 -- Sydney, Australia:

A new class of drug targeting skin cancer's genetic material has been successfully tested in humans for the first time, opening the way to new treatments for a range of conditions from skin cancers to eye diseases.

The research involves the drug Dz13, a targeted molecular therapy, which was developed at the University of New South Wales (UNSW) and has now been found to be safe in a clinical trial of patients with the common skin cancer, basal-cell carcinoma.

"This is the first report of a drug of this type to be used in humans," says UNSW Medicine's Professor Levon Khachigian, who has been developing the DNAzyme technology for 10 years.

"It's a smart drug, which targets a bad protein that controls tumour growth and spread," says Professor Khachigian, the Director of the UNSW Centre for Vascular Research. The collaborative trial was conducted by researchers from UNSW, the University of Sydney and Royal Prince Alfred Hospital.

The findings have been published today in the prestigious journal The Lancet.

"Even though we were only testing for safety, there were unexpected positive effects," says Professor Khachigian.

"The drug knocked down levels of this bad protein and the tumours shrunk in the majority of patients."

The researchers hope subsequent trials will prove that larger doses of the drug over a longer time period will be more effective.

"Targeted molecular therapy like this might also offer novel, effective, and less invasive therapeutic options for basal-cell carcinoma," says Professor Gary Halliday, from the University of Sydney, who is one of the co-authors of the study.

If the next stages of the clinical trials in basal-cell carcinoma are successful, the researchers hope that within three years, the drug could be used as a treatment for these cancers, reducing scarring and the costs and inconvenience associated with surgery.

Basal-cell carcinoma is the most common cancer among fair-skinned people worldwide with Australia having the highest incidence.

"This may be a 'one-size fits all' therapy, because it targets a master regulator gene called c-Jun which appears to be involved in a range of diseases," says Professor Khachigian, who predicts that melanoma and eye diseases including macular degeneration and diabetic retinopathy are the likely future targets for research.

A phase one trial in skin melanoma is expected to begin in a month.


'/>"/>

Contact: Susi Hamilton
susi.hamilton@unsw.edu.au
61-422-934-024
University of New South Wales
Source:Eurekalert

Related medicine news :

1. Parker Waichman LLP Files Class Action Lawsuit on Behalf of Consumers Who’ve Purchased Azek Decking
2. Studio Pulse Announces New Website Making It Easier for Clients to Learn About Their Program and Sign Up for Classes Online
3. Special Learning, Inc. to Bring World-Class Education and Treatment Programs for Special Needs to the Philippines
4. Tools4ever Creates and Launches New Connector between its User Management Resource Administrator and the enterprise-class email solution, Zimbra
5. Celebrate National CPR/AED Week in June by Organizing an American Heart Association CPR & First-Aid Certification Class with Safety Training Seminars
6. San Jose CPR Certification Now Sells AEDs (Automated External Defibrillators) and Teaches CPR/AED Certification Training Classes in San Jose, CA
7. Flavor Your Life Releases Report on Extra Virgin Olive Oil Classification
8. Altman Fitness’ Eden Twin Cities Boot Camp Is Giving Away Classes
9. Class Action Imprelis Lawsuit Filed on Behalf of Multiple Property Owners Who Allege Imprelis Use Caused Extensive Tree Damage and Death, Reports Wright & Schulte
10. Hanley Center Foundation Takes Golf Classic to The Medalist
11. Enterprise Rent-A-Car 8th Annual Golf Classic to Be Held on Thursday, May 9
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... WHAT: , ... and recognition opportunities as well as advocacy for the state and region‘s technology ... February 23. The Council's Innovation Forecast event highlights innovation throughout the region ...
(Date:2/24/2017)... ... 24, 2017 , ... Dr. Ronald E. Hawkins, vice president ... of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean ... Dr. Bell comes to Liberty from the Ohio University Heritage College of Osteopathic ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... In the ... to be a top priority because it’s not if you will be attacked, but ... especially when it comes to digital health care. , Improvements in auditing and monitoring ...
(Date:2/24/2017)... ... ... Healthcare Associates of McKinney announced today that they have moved ... Highway 121, Suite 210, McKinney, Texas 75070. It is in the heart of ... practice has grown, the need for more space has been paramount. This beautiful ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users now have the ability ... total control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass ... , With ProGlass Prism users are given the tools and effects to generate ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)...  Xynomic Pharmaceuticals, Inc., an oncology drug research ... acquired exclusive worldwide rights to develop, manufacture and ... targeting hematological and solid tumors. To ... 2 clinical trials of Abexinostat in US, EU ... been completed, demonstrating that Abexinostat is clinically active ...
(Date:2/23/2017)... Feb. 23, 2017 Visiomed, the French ... since 1997, is changing the landscape of healthcare ... patients with pro-active, custom-made solutions. Recognizing the rising ... and affordable healthcare without walls, Visiomed has launched ... developed with healthcare professionals that is empowering the ...
(Date:2/23/2017)... 2017  Genesis Healthcare Services has merged with Hospice ... by Bill Monast , President and CEO of ... Nathan Feltman , executives with Home Health Depot, Inc., ... This acquisition helps Hospice Cloud maintain its ... durable medical equipment (DME) solutions for the hospice industry. ...
Breaking Medicine Technology: